Skip to main content
SpringerLink
Log in

Neue Ansätze zur Therapieoptimierung

Stand der Dinge beim Rektumkarzinom

  • Zertifizierte Fortbildung
  • Rektumkarzinom
  • Published:
Uro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Springer Medizin Verlag

Abb. 2

Springer Medizin Verlag

Abb. 3

Springer Medizin Verlag

Literatur

  1. Gesellschaft der epidemiologischen Krebsregister in Deutschland, Robert-Koch Institut (2012) Krebs in Deutschland 2007-2008, Häufigkeiten und Trends: Darm, 8. Aufl., 36-9

  2. Majek O, Gondos A, Jansen L et al (2012) Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer 106: 1875-80 https://doi.org/10.1038/bjc.2012.189

  3. Krebsstatistik Austria http://www.statistik.at/web_de/statistiken/gesundheit/krebserkrankungen/dickdarm_enddarm/index.html. Zugegriffen: 24. Sept. 2020

  4. Krebsstatistik Schweiz http://www.bfs.admin.ch/bfs/portal/de/index/infothek/onlinedb/stattab/01.topic.9.html. Zugegriffen: 24.Sept. 2020

  5. (2013) S3-Leitlinie Kolorektales Karzinom. http://www.awmf.org/ leitlinien/detail/ll/021-007OL.html. Zugegriffen: 24. Sept. 2020

  6. Aigner F, Gröne J, Kneist W (2020) Organerhaltende Therapie des Rektumkarzinoms. Coloproctology 42:301. https://doi.org/10.1007/s00053-020-00478-1

  7. Balmana J, Castells A, Cervantes A (2010) Familial colorectal cancer risk: Rectal cancer: ESMO clinical practice guidelines. Ann Oncol 21:v78-v81. https://doi.org/10.1093/annonc/mdq169

  8. Wittekind C, Meyer HJ (2010) TNM Klassifikation maligner Tumoren, 7. Aufl. Wiley-VCH, Weinheim

  9. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479-2516. https://doi.org/10.1093/annonc/mds236

  10. Hong YS et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15(11):1245-1253

  11. Gingert C, Adamina M (2020) Coloproctology 42:317-323

  12. https://www.sages.org/publications/guidelines/clinical-spotlight-review-transanal-minimally-invasive-surgery-tamis/. Zugegriffen: 24. Sept. 2020

  13. You YN et al (2007) Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 245(5):726-733. https://doi.org/10.1097/01.sla.0000252590.95116.4f

  14. Kidane B et al (2015) Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum 58(1):122-140. https://doi.org/10.1097/DCR.0000000000000293

  15. Lu JY et al (2015) Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. Plos One 10(10):e141427. https://doi.org/10.1371/journal.pone.0141427

  16. Jones HJS, alt (2020) Quality of life after rectal-preserving treatment of rectal cancer. Eur J Surg Oncol 46(11):2050-2056. https://doi.org/10.1016/j.ejso.2020.07.018

  17. Galandiuk S, Wieand HS, Moertel CG et al (1992) Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surgery 174:27-32

  18. Minsky BD, Mies C, Recht A et al (1988) Resectable adenocarcinoma of the rectosigmoid and rectum. I Patterns of failure and survival. Cancer 61:1408-1416

  19. Heald RJ, Husband EM, Ryall RD (1982) The mesorectumin rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613-616

  20. Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335-346

  21. Aitken RJ (1996) Mesorectal excision for rectal cancer. Br J Surg 83:214-216

  22. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B (2000) Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group. Basingstoke Bowel Cancer Research Project. Lancet 356:93-96

  23. Leong AF (2000) Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 43(9):1237-1240

  24. Zaheer S et al (1998) Ann Surg 227(6):800-811

  25. Rullier et al (2013) Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum 56(5):560-567

  26. Le Voyer TE et al (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21(15):2912-2919

  27. Camma C et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284(8):1008-1015

  28. Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358(9290):1291-1304. https://doi.org/10.1016/S0140-6736(01)06409-1

  29. Sauer R, Fietkau R, Wittekind C et al (2003) Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 5:406-415

  30. Kapiteijn E, Marijnen C, Nagtegaal I et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638-646

  31. Bujko K et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10):1215-1223

  32. Birgisson H et al (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23(34):8697-8705

  33. Ruppert R, Kube R, Strassburg J, Lewin A, Baral J, Maurer CA, Sauer J, Junginger T, Hermanek P, Merkel S, other members of the OCUM Group (2020) Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based Multimodal therapy trial. J Am Coll Surg 231(4):413-425.e2. https://doi.org/10.1016/j.jamcollsurg.2020.06.023

  34. Kiran RP, Lian L, Lavery IC (2011) Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy? Dis Colon Rectum 54(2):157-163

  35. Rutkowski A et al (2008) Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe? Ann Surg Oncol 15(11):3124-3131

  36. Ha YH et al (2010) Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 252(2):336-340

  37. COLOR II Study Group, Bonjer HJ et al (2015) A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 372:1324-1332

  38. Simillis C et al (2019) Open versus Laparoscopic versus robotic versus Transanal Mesorectal excision for rectal cancer: a systematic review and network meta-analysis. Ann Surg 270(1):59-68. https://doi.org/10.1097/SLA.0000000000003227

  39. Vennix S (2014) Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005200.pub3

  40. Veltcamp Helbach M (2019) Residual mesorectum on postoperative magnetic resonance imaging following transanal total mesorectal excision (TaTME) and laparoscopic total mesorectal excision (LapTME) in rectal cancer. Surg Endosc 33(1):94-102. https://doi.org/10.1007/s00464-018-6279-9

  41. Aigner F et al (2020) Transanale totale mesorektale Exzision - Indikation, Technik, Ergebnisse. Chirurg 91(10):860-869

  42. Jayne D et al (2017) Effect of robotic-assisted vs conventional Laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 318(16):1569-1580 (30,33)

  43. Katsuno H et al (2020) Robotic surgery for rectal cancer: operative technique and review of the literature. J Anus Rectum Colon 4(1):14-24. https://doi.org/10.23922/jarc.2019-037

  44. Vonk-Klaassen SM, de Vocht HM, den Ouden ME, Eddes EH, Schuurmans MJ (2016) Ostomy-related problems and their impact on quality of life of colorectal cancer ostomates: a systematic review. Qual Life Res 25(1):125-133. https://doi.org/10.1007/s11136-015-1050-3

  45. Croese AD, Lonie JM, Trollope AF, Vangaveti VN, Ho YH (2018) A meta-analysis of the prevalence of Low Anterior Resection Syndrome and systematic review of risk factors. Int J Surg 56:234-241. https://doi.org/10.1016/j.ijsu.2018.06.031

  46. Maas M (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9):835-844. https://doi.org/10.1016/S1470-2045(10)70172-8

  47. Dossa F et al (2017) A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2(7):501-513. https://doi.org/10.1016/S2468-1253(17)30074-2

  48. Kim et al (2020) Coloproctology 42:302-308. https://doi.org/10.1007/s00053-020-00475-4

  49. Garcia-Aguilar J et al (2015) Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 16(15):1537-1546. https://doi.org/10.1016/S1470-2045(15)00215-6

  50. van der Valk MJM, IWWD Consortium (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139):2537-2545. https://doi.org/10.1016/S0140-6736(18)31078-X

  51. Maas M et al (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 22(12):3873-3880. https://doi.org/10.1245/s10434-015-4687-9

  52. Dattani M et al (2018) Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg 268(6):955-967. https://doi.org/10.1097/SLA.0000000000002761

  53. Smith JJ et al (2019) Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA 5(4):e185896. https://doi.org/10.1001/jamaoncol.2018.5896

  54. Conroy et al (2020) Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol 38(15_suppl):4007. https://doi.org/10.1200/JCO.2020.38.15_suppl.4007

  55. Hospers et al (2020) Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. J Clin Oncol 38(15_suppl):4006-4006. https://doi.org/10.1200/JCO.2020.38.15_suppl.4006

  56. Sturiale A, Martellucci J, Zurli L, Vaccaro C, Brusciano L, Limongelli P, Docimo L, Valeri A (2017) Long-term functional follow-up after anterior rectal resection for cancer. Int J Colorectal Dis 32(1):83-88. https://doi.org/10.1007/s00384-016-2659-6

  57. Croese AD (2018) A meta-analysis of the prevalence of low anterior resection syndrome and systematic review of risk factors. Int J Surg 56:234-241. https://doi.org/10.1016/j.ijsu.2018.06.031

  58. the LARS International Collaborative Group, Keane C et al (2020) International consensus definition of low anterior resection syndrome. Dis Colon Rectum 63(3):274-284. https://doi.org/10.1097/DCR.0000000000001583

  59. Aigner et al (2020) Coloproctology 42:324-330. https://doi.org/10.1007/s00053-020-00468-3

  60. Ma B et al (2017) What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer 141(5):1052-1065. https://doi.org/10.1002/ijc.30805

  61. Emmertsen KJ, Laurberg S (2012) Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 255:922

  62. Ramage L, Qiu S, Kontovounisios C, Tekkis P, Rasheed S, Tan E (2015) A systematic review of sacral nerve stimulation for low anterior resection syndrome. Colorectal Dis 17(9):762-771. https://doi.org/10.1111/codi.12968

  63. Pachler J (2005) Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004323.pub3

Download references

Author information

Authors and Affiliations

  1. Chirurgische Abteilung, Krankenhaus der Barmherzigen Brüder Graz, Marschallgasse 12, 8020, Graz, Österreich

    Martin Mitteregger &  Felix Aigner

Authors
  1. Martin Mitteregger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Martin Mitteregger gibt an, dass kein finanzieller Interessenkonflikt besteht. Felix Aigner gibt als mögliche Interessenskonflikte an: Honorare von Olympus Deutschland, Kurstutor und Organisator Kiel, Takeda, Expertenworkshop, Johnson & Johnson, Experten-Meeting Hamburg, Norderstedt, Applied Medical, Kurstutor. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitteregger, M., Aigner, F. Stand der Dinge beim Rektumkarzinom. Uro-News 25, 48–59 (2021). https://doi.org/10.1007/s00092-021-4656-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-021-4656-5

Search

Navigation